{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:11:34Z","timestamp":1780481494861,"version":"3.54.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ekir.2026.106532","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:08:36Z","timestamp":1775495316000},"page":"106532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation"],"prefix":"10.1016","volume":"11","author":[{"given":"Ajay K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106532_bib1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/heartjnl-2020-318004","article-title":"Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention","volume":"107","author":"Lamprea-Montealegre","year":"2021","journal-title":"Heart"},{"issue":"4 Suppl 1","key":"10.1016\/j.ekir.2026.106532_bib3","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.02.001","article-title":"US renal data system 2021 annual data report: epidemiology of kidney disease in the United States","volume":"79","author":"Johansen","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106532_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106532_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10557-020-07035-4","article-title":"The potential of albuminuria as a biomarker of diabetic complications","volume":"35","author":"Raja","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ekir.2026.106532_bib7","series-title":"Proteinuria","author":"Haider","year":"2023"},{"key":"10.1016\/j.ekir.2026.106532_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106532_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2026.106532_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100943","article-title":"Efficacy of mineralocorticoid receptor antagonists on kidney and cardiovascular outcomes in patients with chronic kidney disease: an umbrella review","volume":"7","author":"Amornritvanich","year":"2025","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106532_bib11","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106532_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.jrn.2022.09.011","article-title":"Association of eating patterns and diabetic kidney disease in type 2 diabetes: a cross-sectional study","volume":"33","author":"Real Rodrigues","year":"2023","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.ekir.2026.106532_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/nu13051548","article-title":"Animal fat intake is associated with albuminuria in patients with non-alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Abbate","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ekir.2026.106532_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.ajkd.2004.03.022","article-title":"The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study","volume":"44","author":"Barzilay","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106532_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.repc.2014.08.017","article-title":"Prevalence of microalbuminuria in hypertensive patients with or without type 2 diabetes in a Portuguese primary care setting: the RACE (micRoAlbumin sCreening survEy) study","volume":"34","author":"Marques da Silva","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.ekir.2026.106532_bib16","first-page":"227","article-title":"Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease","volume":"14","author":"Li","year":"2024","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.ekir.2026.106532_bib17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106532_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106532_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ekir.2026.106532_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib21","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106532_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd22-as01","article-title":"Standards of medical care in diabetes\u20142022 abridged for primary care providers","volume":"40","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ekir.2026.106532_bib24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.01860217","article-title":"eGFR and albuminuria in relation to risk of incident atrial fibrillation: A meta-analysis of the Jackson Heart study, the multi-ethnic study of atherosclerosis, and the cardiovascular health study","volume":"12","author":"Bansal","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106532_bib25","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.12659\/MSM.903660","article-title":"Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease","volume":"23","author":"Huang","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ekir.2026.106532_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106532_bib27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106532_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54009-3","article-title":"Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2026.106532_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf172","article-title":"Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting","volume":"18","author":"Hsiao","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106532_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106532_bib31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbadis.2010.03.012","article-title":"Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans","volume":"1802","author":"Barton","year":"2010","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ekir.2026.106532_bib32","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2026.106532_bib33","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/ndt\/gfae214","article-title":"Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application","volume":"40","author":"Moedt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106532_bib34","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106532_bib35","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106532_bib36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMra1808786","article-title":"Insights into glomerular filtration and albuminuria","volume":"384","author":"Benzing","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfq471","article-title":"Inflammation, kidney function and albuminuria in the Framingham Offspring cohort","volume":"26","author":"Upadhyay","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106532_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024139","article-title":"Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials","volume":"11","author":"McCullough","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106532_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0003319711423528","article-title":"Microalbuminuria is associated with the severity of coronary artery disease independently of other cardiovascular risk factors","volume":"63","author":"Ozyol","year":"2012","journal-title":"Angiology"},{"key":"10.1016\/j.ekir.2026.106532_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2021.104162","article-title":"Associations between macrovascular and renal microvascular dysfunction in type 2 diabetes and non-diabetes: the HELIUS study","volume":"136","author":"Hayfron-Benjamin","year":"2021","journal-title":"Microvasc Res"},{"key":"10.1016\/j.ekir.2026.106532_bib41","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jch.13979","article-title":"Relationship between high-normal albuminuria and arterial stiffness in Chinese population","volume":"22","author":"Ye","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ekir.2026.106532_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012141","article-title":"Interrelations between arterial stiffness, target organ damage, and cardiovascular disease outcomes","volume":"8","author":"Vasan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2026.106532_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-017-0652-1","article-title":"Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus","volume":"17","author":"Potier","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2026.106532_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00125-015-3799-x","article-title":"Cardiac (82)Rb PET\/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes","volume":"59","author":"von Scholten","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2026.106532_bib45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.amjcard.2013.11.026","article-title":"Relation of albuminuria to coronary microvascular function in patients with chronic kidney disease","volume":"113","author":"Imamura","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ekir.2026.106532_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cardfail.2015.10.009","article-title":"Prevalence of albuminuria in a general population cohort of patients with established chronic heart failure","volume":"22","author":"Odutayo","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.ekir.2026.106532_bib47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2014.05.016","article-title":"Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction","volume":"2","author":"Katz","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ekir.2026.106532_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2015.02.037","article-title":"Is albuminuria a myocardial infarction risk equivalent for atherothrombotic events?","volume":"240","author":"Rein","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2026.106532_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1747493019895206","article-title":"Proteinuria as an independent predictor of stroke: systematic review and meta-analysis","volume":"15","author":"Kelly","year":"2020","journal-title":"Int J Stroke"},{"key":"10.1016\/j.ekir.2026.106532_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/bc.bc_64_20","article-title":"The role of urinary albumin-to-creatinine ratio as a biomarker to predict stroke: a meta-analysis and systemic review","volume":"7","author":"Li","year":"2021","journal-title":"Brain Circ"},{"key":"10.1016\/j.ekir.2026.106532_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.xkme.2021.03.018","article-title":"Kidney function and aortic stiffness, pulsatility, and endothelial function in African Americans: the Jackson Heart study","volume":"3","author":"Nagarajarao","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106532_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106532_bib53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","article-title":"Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review","volume":"1","author":"Flatt","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ekir.2026.106532_bib54","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib57","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2026.106532_bib58","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106532_bib59","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2026.106532_bib60","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury\u2013mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2026.106532_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004854","article-title":"Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"13","author":"Tangri","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.ekir.2026.106532_bib62","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the Figaro-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106532_bib63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/cd23-as01","article-title":"Standards of care in diabetes\u20142023","volume":"41","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ekir.2026.106532_bib64","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease","volume":"22","author":"Schmieder","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106532_bib65","article-title":"Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management","volume":"13","author":"Verma","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.ekir.2026.106532_bib66","first-page":"57","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Acc"},{"key":"10.1016\/j.ekir.2026.106532_bib67","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.healun.2013.09.001","article-title":"Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant","volume":"32","author":"Kirklin","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ekir.2026.106532_bib68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106532_bib69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106532_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11897-012-0129-1","article-title":"Cardiorenal syndrome and the role of ultrafiltration in heart failure","volume":"10","author":"Prosek","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ekir.2026.106532_bib71","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2215\/CJN.02910313","article-title":"Cardiorenal syndrome: ultrafiltration therapy for heart failure\u2014trials and tribulations","volume":"8","author":"Kazory","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106532_bib72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study","volume":"109","author":"McAlister","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106532_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1461754","article-title":"A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2026.106532_bib74","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:22:55Z","timestamp":1780478575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468024926027646"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106532","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106532"}}